Gregory M. Coté

6.3k total citations
151 papers, 3.4k citations indexed

About

Gregory M. Coté is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Gregory M. Coté has authored 151 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Pulmonary and Respiratory Medicine, 64 papers in Oncology and 49 papers in Molecular Biology. Recurrent topics in Gregory M. Coté's work include Sarcoma Diagnosis and Treatment (67 papers), Bone Tumor Diagnosis and Treatments (28 papers) and Chromatin Remodeling and Cancer (10 papers). Gregory M. Coté is often cited by papers focused on Sarcoma Diagnosis and Treatment (67 papers), Bone Tumor Diagnosis and Treatments (28 papers) and Chromatin Remodeling and Cancer (10 papers). Gregory M. Coté collaborates with scholars based in United States, Canada and United Kingdom. Gregory M. Coté's co-authors include Edwin Choy, Douglas B. Sawyer, Francis J. Hornicek, Nathan K. LeBrasseur, Jacson Shen, David C. Harmon, Henry J. Mankin, Thomas A. Miller, Zhenfeng Duan and Ivan Chebib and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Gregory M. Coté

143 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gregory M. Coté United States	35	1.4k	1.3k	1.3k	567	485	151	3.4k
Elizabeth R. Lawlor United States	32	1.6k 1.2×	1.1k 0.9×	1.9k 1.5×	364 0.6×	671 1.4×	91	3.8k
Keila E. Torres United States	32	1.7k 1.2×	1.3k 1.1×	971 0.8×	496 0.9×	297 0.6×	94	3.3k
Eisuke Kobayashi Japan	28	1.2k 0.9×	740 0.6×	1.1k 0.8×	560 1.0×	780 1.6×	137	2.6k
Stephen L. Lessnick United States	32	3.3k 2.4×	1.0k 0.8×	2.9k 2.3×	397 0.7×	1.3k 2.7×	56	5.1k
Damian Medici United States	15	566 0.4×	1.1k 0.9×	2.2k 1.7×	376 0.7×	750 1.5×	19	3.9k
Brian Andrew Van Tine United States	22	1.7k 1.3×	1.6k 1.3×	461 0.4×	142 0.3×	344 0.7×	121	2.7k
Evangelia Pardali Netherlands	30	533 0.4×	815 0.6×	2.2k 1.7×	256 0.5×	617 1.3×	47	3.7k
Zariana Nikolova Switzerland	20	1.4k 1.0×	592 0.5×	748 0.6×	704 1.2×	162 0.3×	53	3.1k
Inge H. Briaire‐de Bruijn Netherlands	29	1.1k 0.8×	714 0.6×	1.0k 0.8×	794 1.4×	467 1.0×	65	2.7k
Sabrina Rossi Italy	24	1.0k 0.7×	636 0.5×	1.0k 0.8×	226 0.4×	483 1.0×	55	2.5k

Countries citing papers authored by Gregory M. Coté

Since Specialization

Citations

This map shows the geographic impact of Gregory M. Coté's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory M. Coté with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory M. Coté more than expected).

Fields of papers citing papers by Gregory M. Coté

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory M. Coté. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory M. Coté. The network helps show where Gregory M. Coté may publish in the future.

Co-authorship network of co-authors of Gregory M. Coté

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory M. Coté. A scholar is included among the top collaborators of Gregory M. Coté based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory M. Coté. Gregory M. Coté is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hanna, Glenn J., Gregory M. Coté, Rashmi Chugh, et al.. (2025). Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma. Cancer Research Communications. 5(5). 767–773.

Tap, William D., Gregory M. Coté, Howard A. Burris, et al.. (2025). Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma. Clinical Cancer Research. 31(11). 2108–2114. 1 indexed citations

Friedmann, Alison M., et al.. (2025). Adult onset wilms tumor. Radiology Case Reports. 20(3). 1755–1759.

Mita, Monica, Alain C. Mita, Miguel A. Villalona‐Calero, et al.. (2024). Abstract PO4-18-07: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in triple negative breast cancer and transcriptionally addicted relapsed or refractory solid tumors. Cancer Research. 84(9_Supplement). PO4–18. 1 indexed citations

Coté, Gregory M., Bose Kochupurakkal, T. Khanh, et al.. (2024). A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors. Clinical Cancer Research. 31(1). 35–44. 4 indexed citations

Fontana, Elisa, Ezra Y. Rosen, Elizabeth K. Lee, et al.. (2024). Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study). JNCI Journal of the National Cancer Institute. 116(9). 1439–1449. 7 indexed citations

Haddox, Candace L., Michael J. Nathenson, Emanuele Mazzola, et al.. (2024). Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates. Clinical Cancer Research. 30(7). 1281–1292. 17 indexed citations

Coté, Gregory M., Candace L. Haddox, Edwin Choy, et al.. (2024). Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma. Clinical Cancer Research. 30(13). 2702–2708. 3 indexed citations

Ordulu, Zehra, Wei‐Ting Hung, Yin P. Hung, et al.. (2023). Sensitivity to ALK-Directed Therapy in Osteosarcoma With an Acquired ALK Rearrangement. JCO Precision Oncology. 7(7). e2300287–e2300287. 1 indexed citations

10.

Sanalkumar, Rajendran, Rui Dong, Yu‐Hang Xing, et al.. (2023). Highly connected 3D chromatin networks established by an oncogenic fusion protein shape tumor cell identity. Science Advances. 9(13). 17 indexed citations

11.

Venkataraman, Vinayak, Suzanne George, & Gregory M. Coté. (2023). Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor. The Oncologist. 28(8). 671–681. 9 indexed citations

12.

Coté, Gregory M., et al.. (2022). Primary Spindle Cell Sarcoma of the Lung with MGA::NUTM1 Fusion: An Extremely Rare Case of a Potentially Emerging Entity and Review of the Literature. International Journal of Surgical Pathology. 30(8). 931–938. 8 indexed citations

13.

Ingham, Matthew, Shing M. Lee, Brian A. Van Tine, et al.. (2022). A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma. Clinical Cancer Research. 29(6). 1031–1039. 8 indexed citations

14.

Wedekind, Mary Frances, Brigitte C. Widemann, & Gregory M. Coté. (2021). Chordoma: Current status, problems, and future directions. Current Problems in Cancer. 45(4). 100771–100771. 30 indexed citations

15.

Miao, Ruoyu, Edwin Choy, Kevin A. Raskin, et al.. (2019). Prognostic Factors in Dedifferentiated Chondrosarcoma: A Retrospective Analysis of a Large Series Treated at a Single Institution. Sarcoma. 2019. 1–10. 27 indexed citations

16.

Gao, Yan, Yunfei Liao, Jacson Shen, et al.. (2016). Evaluation of P‐glycoprotein (Pgp) expression in human osteosarcoma by high‐throughput tissue microarray. Journal of Orthopaedic Research®. 34(9). 1606–1612. 14 indexed citations

17.

Yang, Xiaoqian, Yong Feng, Yan Gao, et al.. (2015). NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo. Gynecologic Oncology. 137(1). 134–142. 10 indexed citations

18.

Shen, Jacson, Gregory M. Coté, Edwin Choy, et al.. (2014). Programmed Cell Death Ligand 1 Expression in Osteosarcoma. Cancer Immunology Research. 2(7). 690–698. 154 indexed citations

19.

LeBrasseur, Nathan K., Gregory M. Coté, Thomas A. Miller, Roger A. Fielding, & Douglas B. Sawyer. (2003). Regulation of neuregulin/ErbB signaling by contractile activity in skeletal muscle. American Journal of Physiology-Cell Physiology. 284(5). C1149–C1155. 86 indexed citations

20.

Raymond, Vincent, Félix Couture, Gregory M. Coté, et al.. (2002). Chromosomal Duplication at the IRID1 Locus on 6p25 Associated With Wide Variability of the Glaucoma Phenotypes. Investigative Ophthalmology & Visual Science. 43(13). 3016–3016. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact